The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC)
- DOI
- 10.1016/j.lungcan.2026.109582
- Published
- 2026-10
- Container
- Lung Cancer
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.lungcan.2026.109582,
title = {The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC)},
author = {Hye Sung Kim and Li Zhang and J. Nicholas Bodor and Margie L. Clapper and Hossein Borghaei and Martin J. Edelman and Yunyun Zhou and Mitchell Cheung and Joseph Treat},
year = {2026},
journal = {Lung Cancer},
doi = {10.1016/j.lungcan.2026.109582},
url = {https://doi.org/10.1016/j.lungcan.2026.109582}
}RIS
TY - JOUR TI - The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC) AU - Hye Sung Kim AU - Li Zhang AU - J. Nicholas Bodor AU - Margie L. Clapper AU - Hossein Borghaei AU - Martin J. Edelman AU - Yunyun Zhou AU - Mitchell Cheung AU - Joseph Treat PY - 2026 JO - Lung Cancer DO - 10.1016/j.lungcan.2026.109582 UR - https://doi.org/10.1016/j.lungcan.2026.109582 ER -
APA
Kim, H. S., Zhang, L., Bodor, J. N., Clapper, M. L., Borghaei, H., Edelman, M. J., Zhou, Y., Cheung, M., & Treat, J. (2026). The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC). Lung Cancer. https://doi.org/10.1016/j.lungcan.2026.109582
Source records
- crossref · retrieved 2026-09-26T17:58:40.115Z